Studies of BH3 domain-mediated mRNA antitumor therapy combined with adoptive T cell therapy on melanoma model (scRNA)
mRNA coding BH3 domains from distinct BH3-only proteins (mPuma@NPs, mBim@NPs) were delivered to tumor site with LNP, the following day, adoptively transferred T cells were treated. Tumors were collected and the CD3+ T cells were sorted for single cell sequenceing.